Program
Anti-PD-1/Anti-TIM-3 Bispecific Antibody LB1410
Its studies are mostly in Uterine Cervical Neoplasms · Lymphoma, led by L & L Bio Co., Ltd., Ningbo, China.
Drug pageAnti-PD-1/Anti-TIM-3 Bispecific Antibody LB1410: every studyAll 3 studies of it, academic ones too, with its approvals, label and forms.Furthest: phase 3, since Sep 4, 20253 company-led studies, 3 open or runningNext primary completion: Dec 30, 2026 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| L & L Bio Co., Ltd., Ningbo, China | 33 open or running | phase 3since Sep 4, 2025 | Apr 27, 2022 | Dec 30, 2026phase 2 · NCT06468358 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 27, 2022First study: phase 1 study in LymphomaFirst studyNCT05357651 · 100 planned · China
- May 31, 2024Phase 2 study in Solid TumorNCT06468358 · 194 planned · China
- Sep 4, 2025Phase 3 study in Uterine Cervical NeoplasmsNCT07177716 · 120 planned · China
Ahead
- Dec 30, 2026Primary completion: phase 2 study in Solid TumorNCT06468358
- Dec 30, 2026Primary completion: phase 1 study in LymphomaNCT05357651
- Dec 2028Primary completion: phase 3 study in Uterine Cervical NeoplasmsNCT07177716
TargetBeta
“A recombinant humanized bispecific antibody directed against both the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and the inhibitory T-cell receptor T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3; TIM3; hepatitis A virus cell”NCIt, by rule
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07177716Uterine Cervical Neoplasms · China | 3 | Not yet recruiting | Dec 2028 | 120 |
| NCT06468358Solid Tumor · China | 2 | Recruiting | Dec 30, 2026 | 194 |
| NCT05357651Lymphoma · China | 1 | Recruiting | Dec 30, 2026 | 100 |
How it is read
Names in the registry
- “LB1410”, 3 entries
Conditions, from the studies’ own filings
- Uterine Cervical Neoplasms, 1 study
- Lymphoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.